Therapeutic Indications

Bexarotene is indicated for:

Cutaneous T-cell lymphoma (CTCL)

Irrespective of gender only Adults (18 years old or older)

Bexarotene is indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) in adult patients refractory to at least one systemic treatment.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 300 mg/m² once daily

Contraindications

Active ingredient Bexarotene is contraindicated in the following cases:

Hepatic insufficiency

No gender/age discrimination

Lactation

No gender/age discrimination

It is unknown whether bexarotene is excreted in human milk. Bexarotene should not be used in breast-feeding mothers.

Pregnancy

No gender/age discrimination

There are no adequate data from the use of bexarotene in pregnant women. Studies in animals have shown reproductive toxicity. Based on the comparison of animal and patient exposures to bexarotene, a margin of safety for human teratogenicity has not been demonstrated. Bexarotene is contraindicated in pregnancy.

If this medicinal product is used inadvertently during pregnancy, or if the patient becomes pregnant while taking this medicinal product, the patient should be informed of the potential hazard to the foetus.

Uncontrolled hypercholesterolaemia

No gender/age discrimination

Uncontrolled thyroid disease

No gender/age discrimination

Uncontrolled hypertriglyceridaemia

No gender/age discrimination

Ongoing systemic infection

No gender/age discrimination

Hypervitaminosis A

No gender/age discrimination

Pancreatitis

No gender/age discrimination